Sanofi reports data from Phase II demyelinating polyneuropathy trial

Sanofi has reported one-year follow-up findings from an ongoing Phase II clinical trial of its complement C1s inhibitor, riliprubart, in chronic inflammatory demyelinating polyneuropathy (CIDP) patients.